VeroScience is a biotechnology company focused on the development of therapies and products to improve human health with a strong pipeline of metabolic disease products and therapies for immunological disorders.
VeroScience is a hybrid of academic environment mindset and industrial focus conducting preclinical and clinical research, utilizing strong academic and pharmaceutical industry collaborations to advance its development programs.
A major platform technology of the company is Circadian Neuroendocrine Resetting Therapy® that is utilized as a generator of multiple therapeutic strategies to treat a variety of disease states. As an example of a therapeutic output of this technology, the circadian timed daily (morning) administration of Cycloset®, a quick release formulation of bromocriptine mesylate, a sympatholytic dopamine D2 receptor agonist and unique insulin sensitizer, was developed for the treatment of type 2 diabetes. Cycloset is approved by the U.S. FDA, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.